Fortrea Holdings Inc
F:K67
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fortrea Holdings Inc
F:K67
|
US |
|
Record PLC
LSE:REC
|
UK |
|
B
|
Brighthouse Financial Inc
LSE:0HPH
|
US |
|
A
|
ABM Industries Inc
XBER:AB4
|
US |
Fortrea Holdings Inc
Fortrea Holdings is a contract research company that helps drugmakers run clinical trials and get new medicines to market. It designs and manages studies for pharmaceutical, biotechnology, and medical device customers, handling tasks like trial setup, patient recruitment, site management, data collection, and regulatory support. In simple terms, Fortrea is hired to do much of the work needed to test whether a product is safe and effective. Its customers are mainly life sciences companies that want outside help with research and development. Fortrea earns money by charging for project-based services and long-running clinical development contracts. The company does not sell drugs itself; it sells the expertise, staff, and systems needed to run trials across many countries and therapeutic areas. What makes Fortrea different is its role in the middle of the drug development chain. It sits between the company discovering a treatment and the regulators who approve it, which makes its business tied to the steady need for clinical testing rather than to consumer demand for a finished product. That gives it a service-based model built around technical know-how, operational execution, and trust with regulated customers.
Fortrea Holdings is a contract research company that helps drugmakers run clinical trials and get new medicines to market. It designs and manages studies for pharmaceutical, biotechnology, and medical device customers, handling tasks like trial setup, patient recruitment, site management, data collection, and regulatory support. In simple terms, Fortrea is hired to do much of the work needed to test whether a product is safe and effective.
Its customers are mainly life sciences companies that want outside help with research and development. Fortrea earns money by charging for project-based services and long-running clinical development contracts. The company does not sell drugs itself; it sells the expertise, staff, and systems needed to run trials across many countries and therapeutic areas.
What makes Fortrea different is its role in the middle of the drug development chain. It sits between the company discovering a treatment and the regulators who approve it, which makes its business tied to the steady need for clinical testing rather than to consumer demand for a finished product. That gives it a service-based model built around technical know-how, operational execution, and trust with regulated customers.
Guidance raised: Fortrea lifted full-year 2026 revenue guidance to $2.62 billion-$2.69 billion and adjusted EBITDA guidance to $205 million-$220 million after a solid first half and better backlog mix.
Bookings improved: Net new business was $720.4 million, book-to-bill was 1.06x for the quarter, and trailing 12-month book-to-bill was 1.12x, with strength led by biotech.
Margins supported: Management said margin improvement is coming from cost savings, better study mix, and stronger operational discipline, with more upside expected from growth and operating leverage over time.
Cash flow positive: Free cash flow was positive $19.9 million in the quarter, and management said it expects positive free cash flow for the rest of 2026 and for the full year.
AI strategy early: Fortrea said most RFPs now ask about AI capabilities, but it is still too early for AI to drive major commercial wins; near-term benefits are mainly operational.
Leadership update: The company disclosed that new CFO Jason Madlock cannot act as CFO right now due to a legal proceeding, and board member David Smith is serving as interim CFO.
